Michael Green, an American molecular biologist and cell biologist at the University of Massachusetts Medical School has died of a stroke recently. Friends and loved ones announced the death through a social media publication made on Twitter. Michael Green was the chair of the Department of Molecular, Cell, and Cancer Biology at the University of Massachusetts Medical School, and also the director of the UMass Cancer Center, and a Howard Hughes Medical Institute investigator.
“Just sharing another sad news with the scientific community. The Pioneering molecular biologist Dr. Michael Green, M.D. Ph.D., HHMI, and NAS member from Umass Med. School, passed away today with a stroke. Dr. Green revolutionized our understanding of transcription factors.”
Who is Michael Green?
Green is a member of the National Academy of Sciences and the National Academy of Medicine. Green graduated from the University of Wisconsin-Madison with a bachelor’s degree in biochemistry. He subsequently continued on to the Washington University School of Medicine, where he earned his M.D. and Ph.D. in biochemistry in 1981 while working under the direction of Robert G. Roeder. Before joining the faculty at Harvard in 1984, he worked as a postdoctoral researcher there under Thomas Maniatis. Since 1990, when he transferred from Harvard to the University of Massachusetts Medical School, he has remained there, where he will pass away in 2023.
READ MORE: Leader of Vietnam Draft Resistance Movement, David Harris Dies at 76
In 2015, he was appointed director of the UMass Cancer Center. Prior to that, he served as chair of the department of molecular, cell, and cancer biology. In 1994, Green joined the Howard Hughes Medical Institute as an investigator. In 2014 and 2015, he was elected to the National Academies of Sciences and Medicine, respectively. Green was a founding member of Fulcrum Therapeutics, a biotechnology business based in Cambridge, Massachusetts.
Research
The focus of research in Green’s lab was on the regulation of genes, especially the regulation of gene transcription and RNA splicing. Using genome-wide RNA interference screens to find genes involved in cell proliferation or apoptosis in the presence of oncogenic mutations, the group also investigates the effects of regulatory patterns on the behavior of cancer cells. Green started researching the uncommon genetic disorder Rett syndrome in 2014.
Funeral plans are pending.
